Overall market performance
According to statistics, the total sales* of China’s hospital pharmaceutical market were RMB 196.4 billion in 2017 Q3 (data source: China hospital drug statistical report of IQVIA, >=100 beds), growing by 6.2% year on year. Based on 12-month MAT (Moving Annual Total**), the MAT growth of 2017 Q3 was 6.2%.
*Sales: Purchase amount of hospital pharmacies
**MAT (Moving Annual Total): The total of figures over the course of the previous 12 months from a designated time node. It means the sales over the course from 2016 Q4 to 2017 Q3 here.
Market performance of multinational enterprises and local Chinese enterprises
The 2017 Q3 sales growth of multinational enterprises was 11.5% in China, significantly growing than the same period of last year, while that of Chinese enterprises was 4.6%, slightly down than the same period of last year. Pfizer, Yangtze River and AstraZeneca separately ranked the top three in enterprise quarterly sales and MAT sales rankings.
Top 10 Hospital Pharmaceutical Product Suppliers in China in 2017 Q3 (by Quarterly Sales)
|
Ranking |
Company |
MAT growth, % |
|
1 |
Pfizer |
14.9% |
|
2 |
Yangtze River Pharmaceutical |
13.4% |
|
3 |
AstraZeneca |
14.9% |
|
4 |
Hengrui Medicine |
17.4% |
|
5 |
Qilu Pharmaceutical |
4.5% |
|
6 |
Sanofi |
11.2% |
|
7 |
Chiatai Tianqing |
10.0% |
|
8 |
Fosun Pharmaceutical |
3.5% |
|
9 |
Sihuan Pharm |
2.4% |
|
10 |
Bayer |
10.7% |
Data source: IQVIA CHPA (China hospital drug statistical report), >=100 beds
Market performance of key therapeutic areas and major products
Categories and products
Seen from the therapeutic areas, in 2017 Q3, Chinese patent medicines achieved 1.7% MAT growth to reach RMB 134.6 billion MAT sales, ranking first among all drug categories; anti-infectives for systemic use achieved 5.0% MAT growth to reach RMB 114 billion MAT sales, ranking second; cardiovascular system drugs, antineoplastic drugs and immunomodulators, central nervous system drugs, blood and blood...
(All Rights Reserved)